Ixekizumab for psoriatic arthritis: safety, efficacy and patient selection

This article was originally published here

J Inflamm Res. December 17, 2021; 14: 6975-6991. doi: 10.2147 / JIR.S229752. Electronic collection 2021.


OBJECTIVE: ixekizumab is a monoclonal antibody targeting IL-17A approved for psoriasis, psoriatic arthritis (RP) and axial spondyloarthritis. The objectives of the review were to summarize: 1) the safety of ixekizumab in people with RP, 2) the efficacy of ixekizumab from phase III randomized controlled trials, and 3) the phenotypes of PR of participants in the ixekizumab study.

METHODS: We searched PubMed limited to phase III randomized controlled trials (RCTs) and corresponding long-term extension studies where the intervention was ixekizumab treatment in a population with RP.

RESULTS: We identified 17 publications and 13 met the inclusion criteria. Injection site reactions (ISRs) and allergic reactions occurred up to 25.3% and 6.2% with ixekizumab and 4.5% and 1.85, respectively, with placebo. RSI occurred in 9.5-10.6% at 24 and 52 weeks with ixekizumab versus 3.2-3.5% with adalimumab (p 92%.

Conclusion: Treatment with ixekizumab in RP was associated with a statistically higher risk of injection site reactions compared to placebo or adalimumab. Ixekizumab had statistically significantly fewer serious adverse events than adalimumab. Ixekizumab has been shown to be effective in all areas of RP disease activity as well as in slowing the radiographic progression of the disease. The main drawback of the ixekizumab PsA program is the lack of representation from African American study participants.

PMID: 34949934 | PMC: PMC8691193 | DOI: 10.2147 / JIR.S229752

Martin E. Berry